Long-term Beta-blocker Therapy After Acute Myocardial Infarction

• Status: Not yet recruiting
• Trial end date: 2026-03-20
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI).

Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Collaborators: Chonbuk National University Hospital; Chonnam National University Hospital; Chosun University Hospital; Chungbuk National University Hospital; Chungnam National University Hospital; Ewha Womans University; Ewha Womans University Seoul Hospital; Gyeongsang National University Hospital; Inje University; Jeju National University Hospital; Kangbuk Samsung Hospital; Keimyung University Dongsan Medical Center; Korea University Anam Hospital; Kyung Hee University Hospital; Presbyterian medical center; Saint Vincent's Hospital, Korea; Samsung Changwon Hospital; Sejong General Hospital; Seoul National University Bundang Hospital; Wonju Severance Christian Hospital; Wonkwang University Hospital
• Treatments: Adrenergic beta-Antagonists

Criteria

Inclusion Criteria:

• Subject must be at least 19 years of age.

• Subject who have been continuing β-blocker therapy for at least 1 year after acute myocardial infarction regardless of the time of diagnosis

• Subject is able to verbally confirm understandings of risks and benefits of this trial, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion Criteria:

• Subject whose left ventricle ejection fraction was less than 40% from echocardiography performed after acute myocardial infarction or who have never received echocardiography.

• Treatment history of heart failure

• Contraindication to β-blocker therapy (history of symptomatic bronchial asthma or chronic obstructive pulmonary disease, 2nd or 3rd degree AV block, cardiac pacemaker implantation, or other cases where β-blocker cannot be used under the judgment of the clinician)

• Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).

• History of atrial fibrillation

• Pregnancy or breast feeding

• Severe renal dysfunction (creatinine clearance < 30 ml/min/1.73 m2)